CDMO News
89bio’s $135M Deal with BiBo Biopharma for Pegozafermin Production
89bio, a San Francisco-based liver and cardiometabolic disease specialist, is making strides in the treatment of metabolic dysfunction-associated steatohepatitis (MASH). The company has recently partnered with China’s BiBo Biopharma Engineering to construct a facility that will produce the bulk active
12 April 2024